The notified product is an oral preparation in the form of a tablet containing sodium butyrate, which consists of: sodium butyrate in the form of 55 -75% weight, hydroxypropyl methylcellulose in the form of 15 -30%weight, magnesium stearate in the form of 0,5 -4%weight, colloidal silicon in the form of 0, 1 -1% weight, inorganic calcium salts in the range of 10 -30% weight； possibly an inner shell which is retarding in the range of 3 -10% weight compared to the core mass, consisting of hydroxypropyl methyl cellulose or ethyl cellulose and hydroxypropyl methyl cellulose in the range of 60 -90%weight, a plasticiser in the range of 8-20%weight,and an anti-caking agent in the mass of 20 -45% weight； milking agent in the quantity of 3 -10% weight in relation to the mass of the core made of poly(acrylic acid-ko-methylmethacrylate-ko-methacrylic methyl) 7:3:1 in the quantity 65 -90% weight, a plasticiser in the quantity of 1 -8%weight, and an anti-caking agent in 5- -35% weight, and possibly an emulsifier when glycerol monostearate is used. In addition, the oral preparation in the form of a capsule containing sodium butyrate consists of: sodium granules in the form of 55-80% weight, high-density hydroxypropyl methylcellulose in the form of 15-40% weight,magnesium stearate in the mass of 0,5 -4%weight, colloidal silicon in the mass of 0,1 -1%weight, possibly inorganic calcium salts in the mass of 10 -30%weight； hard capsule, coated with an envelope of 3-10% weight in relation to the mass of granules, made of poly(acrylated-ko-methylmethacrylic acid) 7:3:1 Quantities 65-90% of weight, plasticiser in quantity 1-8% of weight, anti-caking agent in quantity 5-35% of weight and possibly emulsifier. Possibly an internal retardant enclosure on the capsule below the milking enclosure in 3-10% weight relative to the granular mass,consisting of hydroxypropyl methylcellulose or ethyl cellulose and hydroxypropyl methylcellulose in the quantity of 60- -90% weight, a plasticiser in the qu
